Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management
Open Access
- 8 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 4 (2) , pkz079
Abstract
We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy’s impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n = 235; BEPx4, n = 82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P < .0001). Multivariable modeling assessed associations of risk factors and treatment with hearing impairment, tinnitus, peripheral neuropathy, and Raynaud phenomenon. Risk for each AHO statistically increased with both increasing chemotherapy burden (P < .0001) and selected modifiable risk factors (P < .05): hypertension (odds ratio [OR] = 2.40) and noise exposure (OR ≥ 2.3) for hearing impairment; noise exposure for tinnitus (OR ≥ 1.69); peripheral vascular disease for neuropathy (OR = 8.72); and current smoking for Raynaud phenomenon (OR = 2.41). Clinicians should manage modifiable risk factors for AHOs among TCS.Keywords
Funding Information
- National Cancer Institute (1R01 CA157823)
- Indiana University
This publication has 28 references indexed in Scilit:
- Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular CancerJournal of Clinical Oncology, 2012
- Peripheral Vascular Disease and Peripheral Neuropathy in Individuals With Cardiometabolic Clustering and ObesityDiabetes Care, 2011
- Quality of life among testicular cancer survivors: a case–control study in the United StatesQuality of Life Research, 2011
- Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancerCancer, 2010
- Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer SurvivorsJNCI: Journal of the National Cancer Institute, 2009
- Health Behaviors and Depressive Symptoms in Testicular Cancer SurvivorsUrology, 2007
- Risk Factors for Tinnitus in a Population of Older Adults: The Blue Mountains Hearing StudyEar & Hearing, 2003
- Different factors influencing the expression of Raynaud's phenomenon in men and womenArthritis & Rheumatism, 1999
- Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancerEuropean Journal of Cancer, 1995
- The Relation of Hearing in the Elderly to the Presence of Cardiovascular Disease and Cardiovascular Risk FactorsJAMA Otolaryngology–Head & Neck Surgery, 1993